News & Activities » ProBio CDMO Expands Viral Vector Development Capabilities at US site, Hopewell, New Jersey, with New Packaging Test Platform

ProBio CDMO Expands Viral Vector Development Capabilities at US site with New Packaging Test Platform

Hopewell, New Jersey – April, 2026 — ProBio CDMO has announced the release of its Viral Vector Packaging Test, a new early stage development offering designed to accelerate decision making and de risk progression from discovery to CMC in cell and gene therapy programs. The launch builds on the opening of ProBio’s state of the art viral vector facility in 2025, further strengthening the company’s end to end capabilities in advanced therapies.

The new Viral Vector Packaging Test provides feasibility level data to support vector design, manufacturability, and scalability decisions at a critical inflection point in development. By leveraging ProBio’s proprietary packaging systems and platform processes, the test enables rapid comparative evaluation of packaging strategies with turnaround times as short as three to five weeks, depending on the program design.

Huiyi Zhu, Global Line Manager for Viral Vector, warmly welcomed the release, stating “Early development choices have lasting impact on the success of cell and gene therapy programs,” “This new packaging test reflects our commitment to providing biopharma innovators with practical data, technical confidence, and a clear path forward, using the same systems they can later take into CMC and clinical development.”

Designed for Seamless Scale Up

The Viral Vector Packaging Test supports multiple viral vector modalities, including lentiviral vectors (LVV) for in vivo and ex vivo CAR T applications, and AAV for gene therapy. Key features include:

Consistent development-to-CMC continuity, using the same cell lines and packaging plasmids applied in later-stage manufacturing
Platform upstream and downstream processes to generate representative material
Comprehensive quality assessments, including physical titer, genome purity, endotoxin levels, and full/empty ratio where applicable
Design of Experiments (DoE)–based screening, enabling systematic optimization of plasmid ratios and packaging components for LVV of in vivo CAR-T

The offering is particularly suited for candidate selection, feasibility assessment, and sample generation for pharmacology studies, allowing biopharma innovators to progress with greater speed and confidence.

ProBio’s viral vector facility is purpose built to support scalable, globally compliant cell and gene therapy development and manufacturing. The facility integrates advanced upstream and downstream technologies with quality systems designed to support programs from early research through clinical and commercial stages.

Together, the new facility and the Viral Vector Packaging Test reinforce ProBio’s position as a strategic CDMO partner for innovators seeking accelerated development timelines without compromising technical rigor or future readiness.

About ProBio CDMO

ProBio CDMO is a global contract development and manufacturing organization specializing in cell and gene therapies. With integrated capabilities spanning discovery support, process development, GMP manufacturing, and quality services, ProBio partners with biotech and pharmaceutical companies to translate innovative science into impactful therapies.

For more information, visit www.ProBioCDMO.com.